Physician profile
Stephen Huang
NPI 1124089685
$11,873.59
in general payments reported to CMS, 2019-2025
49 companies · $4,510 in 2025
The $4,510 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,608 · 2020: $965 · 2021: $1,031 · 2022: $624 · 2023: $370 · 2024: $766 · 2025: $4,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Food and Beverage: $1,904 · Travel and Lodging: $1,741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Food and Beverage | $1,904.28 |
| Travel and Lodging | $1,741.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avyxa Pharma, LLC | $4,049.98 | 2025 | |
| Amgen INC. | $686.47 | 2019-2021 | |
| Incyte Corporation | $631.67 | 2019-2024 | Jakafi |
| Astrazeneca Pharmaceuticals Lp | $629.91 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $472.94 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $414.26 | 2019-2025 | |
| Pfizer INC. | $387.20 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $334.23 | 2019-2025 | |
| Abbvie INC. | $329.25 | 2022-2025 | |
| Genzyme Corporation | $314.00 | 2019-2022 | |
| Janssen Biotech, INC. | $291.88 | 2019-2024 | Tecvayli, Darzalex |
| Merck Sharp & Dohme LLC | $241.22 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $199.72 | 2019-2020 | |
| Genentech USA, INC. | $199.35 | 2019-2021 | |
| Rigel Pharmaceuticals, INC. | $170.58 | 2019-2024 | Rezlidhia, Tavalisse |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.